國立虎尾科技大學 |

Melatonin, neuroprotective agents and antidepressant therapy

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Melatonin, neuroprotective agents and antidepressant therapy/ edited by Francisco Lopez-Munoz ... [et al.].
其他作者:	Lopez-Munoz, Francisco.
出版者:	New Delhi :Springer India : : 2016.,
面頁冊數:	xxv, 921 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
標題:	Melatonin. -
電子資源:	http://dx.doi.org/10.1007/978-81-322-2803-5
ISBN:	9788132228035

Melatonin, neuroprotective agents and antidepressant therapy
Melatonin, neuroprotective agents and antidepressant therapy[electronic resource] /edited by Francisco Lopez-Munoz ... [et al.]. - New Delhi :Springer India :2016. - xxv, 921 p. :ill., digital ;24 cm.

This work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agents like agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects.

ISBN: 9788132228035

Standard No.: 10.1007/978-81-322-2803-5doiSubjects--Topical Terms:

970528
Melatonin.

LC Class. No.: RM297.M44

Dewey Class. No.: 615.78

Melatonin, neuroprotective agents and antidepressant therapy
LDR:02491nam a2200301 a 4500 001 868344
003 DE-He213
005 20161117101939.0
006 m d
007 cr nn 008maaau
008 170720s2016 ii s 0 eng d
020 $a 9788132228035 $q (electronic bk.)
020 $a 9788132228011 $q (paper)
024 7 $a 10.1007/978-81-322-2803-5 $2 doi
035 $a 978-81-322-2803-5
040 $a GP $c GP
041 0 $a eng
050 4 $a RM297.M44
072 7 $a MJN $2 bicssc
072 7 $a MED056000 $2 bisacsh
082 0 4 $a 615.78 $2 23
090 $a RM297.M44 $b M517 2016
245 0 0 $a Melatonin, neuroprotective agents and antidepressant therapy $h [electronic resource] / $c edited by Francisco Lopez-Munoz ... [et al.].
260 $a New Delhi : $c 2016. $b Springer India : $b Imprint: Springer,
300 $a xxv, 921 p. : $b ill., digital ; $c 24 cm.
520 $a This work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agents like agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects.
650 0 $a Melatonin. $3 970528
650 0 $a Melatonin $x Therapeutic use. $3 1023961
650 0 $a Antidepressants. $3 783739
650 0 $a Medicine. $3 644133
650 0 $a Internal medicine. $3 644638
650 0 $a Neurology. $3 593894
650 0 $a Psychopharmacology. $3 644799
650 1 4 $a Medicine & Public Health. $3 593949
650 2 4 $a Internal Medicine. $3 668583
700 1 $a Lopez-Munoz, Francisco. $3 1115888
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-81-322-2803-5
950 $a Medicine (Springer-11650)